Table of Contents
Volume 4 | Issue 2
Publication Date: September 2003- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Meeting Highlights | ||
73-78 |
From: 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois Jennifer Klem, Kavita Maung, Angelia Gibson, Vinay K. Jain |
|
Researches in Brief | ||
79-82 |
Phase II Trials of Bortezomib (PS-341, Velcade™) A Selective Proteasome Inhibitor, in Non-Hodgkin’s Lymphoma Angelia D. Gibson, Vinay K. Jain |
|
83-85 |
Impact of Dose-Intense and Dose-Dense Approaches on Outcome in Aggressive Non-Hodgkin’s Lymphoma Angelia D. Gibson, Vinay K. Jain |
|
Comprehensive Review | ||
86-92 |
Acquired Immunodeficiency Syndrome–Related Lymphoma in the Era of Highly Active Antiretroviral Therapy Christina Thirlwell, Debashis Sarker, Justin Stebbing, Mark Bower |
|
Original Contributions | ||
93-98 |
Fourteen-Day CHOP Supported with Granulocyte Colony-Stimulating Factor in Patients with Aggressive Non-Hodgkin’s Lymphoma: Results of a Phase II Study Stephanie A. Gregory, Delvyn C. Case, Jr, Linda Bosserman, Debra L. Litwak, William R. Berry, Leonard A. Kalman, Robert J. Belt, Alan Saven |
|
99-103 |
Primary Gastrointestinal Non-Hodgkin’s Lymphoma: Treatment Outcome Salem H. Al-Shemmari, Kamlesh P. Sajnani, Reem M. Ameen, Ahmed M. Ragheb |
|
Translational Medicine | ||
104-111 |
Lymphomas and Oncolytic Virus Therapy Tommy Alain, Chandini Thirukkumaran, Donald G. Morris, Stefan J. Urbanski, Anna Janowska-Wieczorek, Patrick W.K. Lee, Anna E. Kossakowska |
|
Case Reports | ||
112-114 |
Multimodality Treatment in a Case of Primary Cardiac Lymphoma Shelly S. Lo, Andrew M.Yeager, Robert L. Peel, William E. Katz, Ramesh K. Ramanathan |
|
115-118 |
Rituximab in Lymphocyte Predominance Hodgkin’s Disease: A Case Series Valerie K. Ibom, Robert G. Prosnitz, Jerald Z. Gong, Joseph O. Moore, Carlos M. DeCastro, Leonard R. Prosnitz, David A. Rizzieri, Jon P. Gockerman |
|
Current Trial | ||
119-122 |
A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Bortezomib (PS-341, Velcade™) and Melphalan in Patients with Relapsed or Refractory Multiple Myeloma Hank H. Yang, Robert Vescio, David Schenkein, James R. Berenson |
|